Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Tafamidis Free Acid in Healthy Subjects
NCT02406560Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (3 arms), sponsored by Pfizer. Primary endpoints: Area under the Concentration-Time Curve at 168 hours and Maximum Observed Plasma Concentration at 168 hours. Started Apr 2015; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT02406560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406560.